Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
GTBP Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-2.68%
Day range:
$0.79 - $0.85
52-week range:
$0.54 - $3.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
59.35x
P/B ratio:
3.00x
Volume:
1.5M
Avg. volume:
1.8M
1-year change:
-73.59%
Market cap:
$9M
Revenue:
--
EPS (TTM):
-$3.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.60 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.5M | -$0.04 | -1.06% | -93.96% | $7.16 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $788.28 |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.08 | -- | -19.51% | $6.83 |
|
XNCR
Xencor, Inc.
|
$28.7M | -$0.70 | -43.18% | -6.09% | $28.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
$0.85 | $8.00 | $9M | -- | $0.00 | 0% | 59.35x |
|
GERN
Geron Corp.
|
$1.40 | $3.60 | $893.7M | -- | $0.00 | 0% | 5.08x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.57 | $7.16 | $78.6M | -- | $0.00 | 0% | 9.16x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$783.71 | $788.28 | $82.4B | 18.76x | $0.88 | 0.45% | 6.06x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
$2.84 | $6.83 | $404.5M | -- | $0.00 | 0% | -- |
|
XNCR
Xencor, Inc.
|
$15.45 | $28.25 | $1.1B | -- | $0.00 | 0% | 7.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -0.931 | 0.02% | 1.22x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 2.404 | 0.3% | 7.50x |
|
XNCR
Xencor, Inc.
|
24.45% | 1.841 | 24.19% | 5.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
|
XNCR
Xencor, Inc.
|
$18.4M | -$47.5M | -15.54% | -20.07% | -226.29% | -$31M |
GT Biopharma, Inc. vs. Competitors
-
Which has Higher Returns GTBP or GERN?
Geron Corp. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -39.02%. GT Biopharma, Inc.'s return on equity of -626.24% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About GTBP or GERN?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 846.75%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 157.14%. Given that GT Biopharma, Inc. has higher upside potential than Geron Corp., analysts believe GT Biopharma, Inc. is more attractive than Geron Corp..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 GERNGeron Corp.3 1 1 -
Is GTBP or GERN More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock GTBP or GERN?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or GERN?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Geron Corp.'s net income of -$18.4M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 5.08x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M GERNGeron Corp.5.08x -- $47.2M -$18.4M
-
Which has Higher Returns GTBP or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -316.61%. GT Biopharma, Inc.'s return on equity of -626.24% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About GTBP or PSTV?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 846.75%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1151.53%. Given that Plus Therapeutics, Inc. has higher upside potential than GT Biopharma, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than GT Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 PSTVPlus Therapeutics, Inc.3 0 0 -
Is GTBP or PSTV More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.692%.
-
Which is a Better Dividend Stock GTBP or PSTV?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or PSTV?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 9.16x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M PSTVPlus Therapeutics, Inc.9.16x -- $1.4M -$4.4M
-
Which has Higher Returns GTBP or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of 38.89%. GT Biopharma, Inc.'s return on equity of -626.24% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About GTBP or REGN?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 846.75%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that GT Biopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is GTBP or REGN More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock GTBP or REGN?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or REGN?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. GT Biopharma, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M REGNRegeneron Pharmaceuticals, Inc.6.06x 18.76x $3.8B $1.5B
-
Which has Higher Returns GTBP or SLS?
SELLAS Life Sciences Group, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of --. GT Biopharma, Inc.'s return on equity of -626.24% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M -
What do Analysts Say About GTBP or SLS?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 846.75%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 140.61%. Given that GT Biopharma, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe GT Biopharma, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 SLSSELLAS Life Sciences Group, Inc.2 0 0 -
Is GTBP or SLS More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.508, suggesting its more volatile than the S&P 500 by 150.829%.
-
Which is a Better Dividend Stock GTBP or SLS?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or SLS?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than SELLAS Life Sciences Group, Inc. quarterly revenues of --. GT Biopharma, Inc.'s net income of -$3.1M is higher than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M
-
Which has Higher Returns GTBP or XNCR?
Xencor, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -28.7%. GT Biopharma, Inc.'s return on equity of -626.24% beat Xencor, Inc.'s return on equity of -20.07%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M XNCRXencor, Inc.87.62% -$0.08 $827.7M -
What do Analysts Say About GTBP or XNCR?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 846.75%. On the other hand Xencor, Inc. has an analysts' consensus of $28.25 which suggests that it could grow by 82.85%. Given that GT Biopharma, Inc. has higher upside potential than Xencor, Inc., analysts believe GT Biopharma, Inc. is more attractive than Xencor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 XNCRXencor, Inc.9 1 0 -
Is GTBP or XNCR More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.
-
Which is a Better Dividend Stock GTBP or XNCR?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or XNCR?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Xencor, Inc.'s net income of -$6M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 7.60x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M XNCRXencor, Inc.7.60x -- $21M -$6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
